International: Buyer announced for Nestle’s divested infant-nutrition licenses
Just days after it was announced that Nestle SA would agree to find a buyer for its licenses of infant formula as part of a deal to acquire Pfizer Inc., Aspen Pharmacare Holdings Ltd., based in South Africa, has struck a deal to buy the licenses that will allow the company to sell infant formula in Australia, South Africa and Namibia. Antitrust regulators in Australia have reportedly approved of the deal, while those in South Africa and Namibia are pending approval, according to Aspen. Aspen is the largest generic medicine producer in the Southern Hemisphere, supplying medicine to more than 150 countries. The move is part of a larger effort to expand businesses within Australia, Latin America and sub-Sahara Africa.
Featured News
EU Antitrust Chief Raises Concerns Over Big Tech Control of AI
Mar 12, 2026 by
CPI
Burson Adds Senior Advisor to Strengthen Competition Team
Mar 12, 2026 by
CPI
South Korea Fines Pork Processors for Price-Fixing in Retail Supply Deals
Mar 12, 2026 by
CPI
What New York’s New BNPL Rules Mean for Consumers and Lenders
Mar 12, 2026 by
CPI
SEC and CFTC Strike Agreement to Coordinate Crypto Oversight and Market Regulation
Mar 12, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece